Sleep Disturbances and Pulmonary Artery/Aorta Diameter in Scleroderma Patient (Scleroderma)
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Males, Females and Minorities
Age range of subjects 18-75 years old
Description
Inclusion Criteria:
- Patient must have Scleroderma
Exclusion Criteria:
- Patients who do not have Scleroderma
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Arunabh Talwar, MD, Northwell Health
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Cardiovascular Diseases
- Vascular Diseases
- Nervous System Diseases
- Skin Diseases
- Respiratory Tract Diseases
- Sleep Wake Disorders
- Lung Diseases
- Connective Tissue Diseases
- Hypertension
- Dyssomnias
- Parasomnias
- Scleroderma, Systemic
- Scleroderma, Diffuse
- Hypertension, Pulmonary
- Scleroderma, Localized
Other Study ID Numbers
Other Study ID Numbers
- 06-08-018
- NS-LIJHS IRB #06-08-018
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Hypertension
-
NCT07487441Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)
-
NCT07612657Not yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
NCT07217522RecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder) | Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
-
NCT07172334Not yet recruitingChronic Thromboembolic Pulmonary Hypertension (CTEPH) | Pulmonary Arterial Hypertension (PAH)
-
NCT03205085UnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
-
NCT07632898Not yet recruitingPulmonary Arterial Hypertension (PAH)
-
NCT07604805RecruitingIdiopathic Pulmonary Hypertension
-
NCT07266519Not yet recruiting
-
NCT07601295Not yet recruitingPulmonary Arterial Hypertension (PAH)
-
NCT07457762RecruitingPulmonary Arterial Hypertension (PAH)